Atossa Genetics (ATOS) Expected to Announce Earnings on Tuesday

Atossa Genetics (NASDAQ:ATOS) is expected to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Atossa Genetics to post earnings of ($1.04) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Atossa Genetics (NASDAQ:ATOS) last issued its earnings results on Friday, May 8th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, analysts expect Atossa Genetics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Atossa Genetics Stock Performance

Shares of ATOS stock traded up $0.12 on Tuesday, reaching $2.29. 19,280 shares of the company’s stock traded hands, compared to its average volume of 132,585. The company has a market capitalization of $19.72 million, a P/E ratio of -0.71 and a beta of 1.29. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35. The business’s 50 day moving average price is $2.84 and its two-hundred day moving average price is $4.66.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Rodman & Renshaw started coverage on Atossa Genetics in a research note on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price on the stock. Ascendiant Capital Markets lowered their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Finally, Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.33.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATOS. State Street Corp grew its stake in shares of Atossa Genetics by 31.2% in the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after buying an additional 141,990 shares in the last quarter. Geode Capital Management LLC increased its holdings in Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after buying an additional 9,627 shares during the last quarter. Bank of America Corp DE raised its position in Atossa Genetics by 55.8% during the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after acquiring an additional 55,568 shares in the last quarter. Squarepoint Ops LLC raised its position in Atossa Genetics by 39.9% during the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after acquiring an additional 72,235 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Atossa Genetics during the second quarter valued at approximately $381,000. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.